cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAFV600E mutation

2019/03/08 by David W. Ellison, Cynthia Hawkins, David Jones +6 · 27 citations
Medicine · #Glioma Diagnosis and Treatment #Meningioma and schwannoma management #Radiomics and Machine Learning in Medical Imaging

paper · doi:10.1007/s00401-019-01987-0

Citations

• Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology
• The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
• cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV”

Cited by

• The 2021 WHO Classification of Tumors of the Central Nervous System: a summary
• The 2021 World Health Organization Classification of Tumors of the Central Nervous System: What Neuroradiologists Need to Know
• cIMPACT-NOW: a practical summary of diagnostic points from Round 1 updates. [europepmc]
• Molecular pathology of tumors of the central nervous system. [europepmc]
• The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients. [europepmc]
• Isomorphic diffuse glioma is a morphologically and molecularly distinct tumour entity with recurrent gene fusions of MYBL1 or MYB and a benign disease course. [europepmc]
• A single-center study of the clinicopathologic correlates of gliomas with a MYB or MYBL1 alteration. [europepmc]
• Targeted fusion analysis can aid in the classification and treatment of pediatric glioma, ependymoma, and glioneuronal tumors. [europepmc]
• NTRK Fusions in Central Nervous System Tumors: A Rare, but Worthy Target. [europepmc]
• FGFR- gene family alterations in low-grade neuroepithelial tumors. [europepmc]
• The molecular characteristics of spinal cord gliomas with or without H3 K27M mutation. [europepmc]
• A tailored next-generation sequencing panel identified distinct subtypes of wildtype IDH and TERT promoter glioblastomas. [europepmc]
• Clinical Management of Diffuse Low-Grade Gliomas. [europepmc]
• MYB oncoproteins: emerging players and potential therapeutic targets in human cancer. [europepmc]
• Challenges and Opportunities of Intraoperative 3D Ultrasound With Neuronavigation in Relation to Intraoperative MRI. [europepmc]
• The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. [europepmc]
• Prognostic and Predictive Biomarkers in Gliomas. [europepmc]
• Toll-like receptors and toll-like receptor-targeted immunotherapy against glioma. [europepmc]
• The oncogenic fusion landscape in pediatric CNS neoplasms. [europepmc]
• Major Features of the 2021 WHO Classification of CNS Tumors. [europepmc]
• Updates in IDH-Wildtype Glioblastoma. [europepmc]
• The 2021 World Health Organization Classification of Tumors of the Central Nervous System: What Neuroradiologists Need to Know. [europepmc]
• The University of Pennsylvania glioblastoma (UPenn-GBM) cohort: advanced MRI, clinical, genomics, & radiomics. [europepmc]
• Adult type diffuse gliomas in the new 2021 WHO Classification. [europepmc]
• Signaling pathways in brain tumors and therapeutic interventions. [europepmc]
• Glioblastoma multiforme: insights into pathogenesis, key signaling pathways, and therapeutic strategies. [europepmc]
• Glioblastoma at the crossroads: current understanding and future therapeutic horizons. [europepmc]